⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AGEN News
Agenus Inc.
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
businesswire.com
AGEN
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
businesswire.com
AGEN
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
businesswire.com
AGEN
Form 8-K
sec.gov
AGEN
Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight
globenewswire.com
AGEN
EXEL
ABBV
BMY
MRK
LYEL
PFE
BNTX
NVDA
IBM
GEHC
ABT
QGEN
TMO
DHR
MYGN
ILMN
EXAS
INV
Form 8-K
sec.gov
AGEN
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
businesswire.com
AGEN
INKT
Ligand Reports First Quarter 2026 Financial Results
globenewswire.com
LGND
XOMA
MRK
SNDX
AGEN
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update
businesswire.com
AGEN
Agendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast Cancer
businesswire.com
AGEN